| Thomas L Elton, OD | |
|
7000 York Ave S, Edina, MN 55435-4213 | |
| (952) 929-1159 | |
| (952) 922-9308 |
| Full Name | Thomas L Elton |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 13 Years |
| Location | 7000 York Ave S, Edina, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134416605 | NPI | - | NPPES |
| 3231 | Other | MN | MN OD LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152WC0802X | Optometrist - Corneal And Contact Management | 3231 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elton Eyecare Inc | 9032455936 | 10 |
News Archive
The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy.
Congenital diaphragmatic hernia (CDH) is not as well known as muscular dystrophy and cystic fibrosis, but like them it is a life-threatening birth defect, and is just as common. Occurring in one in 3,000 births, CDH causes the guts and liver to protrude through a defective diaphragm and into the chest cavity, where they interfere with the lungs.
New research shows the UK's COVID-19 management decisions were based on an outdated pandemic modelling structure and suggests a more resilient approach would have been more effective.
drugstore.com, inc., a leading online retailer of health, beauty, vision and pharmacy products, today announced that it has entered into an agreement with BioScrip, Inc. (BIOS), through its BioScrip Pharmacy Services subsidiary, to sell the assets of its pharmacy subsidiary and to have BioScrip provide, through a strategic partnership, pharmacy services to drugstore.com customers. drugstore.com expects its customers' transition to the new platform to be seamless.
BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy (DMD). The Phase 1 clinical trial was a single-center, double-blind, placebo-controlled, single-dose escalation study followed by a multiple-dose escalation study in healthy volunteers.
› Verified 2 days ago
| Provider Name | Elton Eyecare Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1811430226 PECOS PAC ID: 9032455936 Enrollment ID: O20190115000305 |
News Archive
The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy.
Congenital diaphragmatic hernia (CDH) is not as well known as muscular dystrophy and cystic fibrosis, but like them it is a life-threatening birth defect, and is just as common. Occurring in one in 3,000 births, CDH causes the guts and liver to protrude through a defective diaphragm and into the chest cavity, where they interfere with the lungs.
New research shows the UK's COVID-19 management decisions were based on an outdated pandemic modelling structure and suggests a more resilient approach would have been more effective.
drugstore.com, inc., a leading online retailer of health, beauty, vision and pharmacy products, today announced that it has entered into an agreement with BioScrip, Inc. (BIOS), through its BioScrip Pharmacy Services subsidiary, to sell the assets of its pharmacy subsidiary and to have BioScrip provide, through a strategic partnership, pharmacy services to drugstore.com customers. drugstore.com expects its customers' transition to the new platform to be seamless.
BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy (DMD). The Phase 1 clinical trial was a single-center, double-blind, placebo-controlled, single-dose escalation study followed by a multiple-dose escalation study in healthy volunteers.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas L Elton, OD Po Box 1170, Maple Grove, MN 55311-6170 Ph: (763) 746-2094 | Thomas L Elton, OD 7000 York Ave S, Edina, MN 55435-4213 Ph: (952) 929-1159 |
News Archive
The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy.
Congenital diaphragmatic hernia (CDH) is not as well known as muscular dystrophy and cystic fibrosis, but like them it is a life-threatening birth defect, and is just as common. Occurring in one in 3,000 births, CDH causes the guts and liver to protrude through a defective diaphragm and into the chest cavity, where they interfere with the lungs.
New research shows the UK's COVID-19 management decisions were based on an outdated pandemic modelling structure and suggests a more resilient approach would have been more effective.
drugstore.com, inc., a leading online retailer of health, beauty, vision and pharmacy products, today announced that it has entered into an agreement with BioScrip, Inc. (BIOS), through its BioScrip Pharmacy Services subsidiary, to sell the assets of its pharmacy subsidiary and to have BioScrip provide, through a strategic partnership, pharmacy services to drugstore.com customers. drugstore.com expects its customers' transition to the new platform to be seamless.
BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy (DMD). The Phase 1 clinical trial was a single-center, double-blind, placebo-controlled, single-dose escalation study followed by a multiple-dose escalation study in healthy volunteers.
› Verified 2 days ago
Dr. Tamra L Larson, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3300 Edinborough Way Ste 412, Edina, MN 55435 Phone: 952-835-3201 | |
Dr. Paul J Shlafer, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3333 Hazelton Rd, Edina, MN 55435 Phone: 952-926-5300 Fax: 952-926-2729 | |
Dr. Joel Woods, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2915 Southdale Ctr, Edina, MN 55435 Phone: 952-920-8607 | |
Dr. Kim Thi Nguyen, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2195 Southdale Ctr, Edina, MN 55435 Phone: 952-920-8607 | |
Toni Albrecht, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3380 Galleria, Edina, MN 55435 Phone: 952-920-5458 | |
Deanna E Harter, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3939 W 50th St Ste 200, Edina, MN 55424 Phone: 952-920-2020 Fax: 952-920-3225 |